Delcath Systems Reports Director Departure and Shareholder Votes

Delcath Systems Inc. (DCTH) reported the departure of a director and the outcome of matters voted on by security holders in a Form 8-K filed with the SEC on May 14, 2026.

The filing, submitted under Items 5.02, 5.07 and 9.01, identifies one board-level change and lists specific proposals and vote tallies from the annual meeting. Item 5.02 covers the departure or election of directors or principal officers; Item 5.07 reports submission of matters to a vote of security holders; Item 9.01 addresses financial statements and exhibits.

Scope of the board change is limited to a single director position on a board that, prior to the departure, consisted of the number required by the company's bylaws and Delaware corporate law. The shareholder meeting involved votes that directly affect governance of the company, which maintains a commercial-stage oncology business focused on its HEPZATO Kit for liver-directed therapy.

The operational delta is a reduction in active directors by one, effective on or before the May 14 filing date. The prior state included the departed director's participation in board and committee work; the new state removes that participation until a replacement is elected. The filing does not cite a cause for the departure and does not name a successor.

Downstream consequences include the obligation to update any committee assignments that involved the departed director, the need to maintain the minimum number of independent directors required by Nasdaq listing rules, and the preparation of a potential proxy statement for the next annual meeting that will reflect the current board composition.

The company must also ensure continued compliance with Section 16 reporting for remaining insiders and may need to file a separate 8-K if a new director is appointed within the standard four-business-day window. Standard SEC rules require the company to exhibit any related board resolutions or agreements as part of the 8-K exhibits.

This filing constitutes the official record of the board change and vote results for the period ending in May 2026. Delcath last reported similar governance updates in prior 8-K filings that disclosed annual meeting results and director elections under the same Item numbers.